Literature DB >> 8926108

Prolonged and preferential production of polymeric immunoglobulin A in response to Streptococcus pneumoniae capsular polysaccharides.

S Johnson1, N L Opstad, J M Douglas, E N Janoff.   

Abstract

Streptococcus pneumoniae is an invasive mucosal pathogen for which host defense is dependent on capsular polysaccharide-specific antibody. Capsule-specific immunoglobulin G (IgG), IgM, and IgA are produced following pneumococcal vaccination and infection. Serum IgA has two molecular forms, polymeric and monomeric. These forms may modulate the avidity of antigen binding and evolve over time as the immune response matures. Therefore, we sequentially characterized the molecular forms of serum IgA to three serotypes of pneumococcal capsular polysaccharides (types 8, 12F, and 14) after pneumococcal vaccination and after natural infection with type 14 S. pneumoniae. Although typically the form of IgA in antigen-specific systemic responses to protein antigens is predominantly polymeric in sera of patients shortly after exposure and shifts to the monomeric form in sera obtained several weeks later, the form of IgA in response to each pneumococcal capsular polysaccharide remained predominantly polymeric 1 month after natural infection and up to I year following vaccination. In contrast, IgA to pneumococcal cell wall polysaccharide was both polymeric and monomeric. Moreover, the form of IgA in response to polyribosyl-ribitol-phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b, was predominantly monomeric in the sera of 8 of 10 subjects tested 1 to 3 months after vaccination with either PRP alone or the diphtheria toxoid conjugate of PRP. We conclude that systemic responses to pneumococcal capsular polysaccharides are distinct in the production of predominantly polymeric IgA over time. The persistence of polymeric IgA may facilitate binding and clearance of pneumococci from the systemic circulation or reflect limited maturation of the immune response to pneumococcal capsular polysaccharides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926108      PMCID: PMC174376          DOI: 10.1128/iai.64.10.4339-4344.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Activation of complement by human serum IgA, secretory IgA and IgA1 fragments.

Authors:  P S Hiemstra; J Biewenga; A Gorter; M E Stuurman; A Faber; L A van Es; M R Daha
Journal:  Mol Immunol       Date:  1988-06       Impact factor: 4.407

2.  A polymeric IgA response in serum can be produced by parenteral immunization.

Authors:  F Mascart-Lemone; J Duchateau; M E Conley; D L Delacroix
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

3.  Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies.

Authors:  C Lue; A Tarkowski; J Mestecky
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

Review 4.  Immunoglobulin A: strategic defense initiative at the mucosal surface.

Authors:  B J Underdown; J M Schiff
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?

Authors:  M E Conley; D L Delacroix
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

6.  Acute antibody responses to Giardia lamblia are depressed in patients with AIDS.

Authors:  E N Janoff; P D Smith; M J Blaser
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

7.  Complement-dependent opsonization of incompatible erythrocytes by human secretory IgA.

Authors:  M E Kaplan; A P Dalmasso; M Woodson
Journal:  J Immunol       Date:  1972-01       Impact factor: 5.422

8.  Kinetics of anti-Campylobacter jejuni monomeric and polymeric immunoglobulin A1 and A2 responses in serum during acute enteritis.

Authors:  F O Mascart-Lemone; J R Duchateau; J Oosterom; J P Butzler; D L Delacroix
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

9.  Human serum antibody response to Campylobacter jejuni infection as measured in an enzyme-linked immunosorbent assay.

Authors:  M J Blaser; D J Duncan
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Activation of the alternative pathway of complement by human serum IgA.

Authors:  P S Hiemstra; A Gorter; M E Stuurman; L A Van Es; M R Daha
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

View more
  7 in total

1.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

2.  Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes.

Authors:  E N Janoff; C Fasching; J M Orenstein; J B Rubins; N L Opstad; A P Dalmasso
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 3.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Pneumococcal IgA1 protease subverts specific protection by human IgA1.

Authors:  E N Janoff; J B Rubins; C Fasching; D Charboneau; J T Rahkola; A G Plaut; J N Weiser
Journal:  Mucosal Immunol       Date:  2013-07-03       Impact factor: 7.313

5.  Mactinin: a modulator of the monocyte response to inflammation.

Authors:  Sharon D Luikart; Hollis E Krug; Robert D Nelson; Timothy Hinkel; Peter Majeski; Pankaj Gupta; Maren L Mahowald; Theodore Oegema
Journal:  Arthritis Res Ther       Date:  2003-08-05       Impact factor: 5.156

6.  Reduced Number of Transitional and Naive B Cells in Addition to Decreased BAFF Levels in Response to the T Cell Independent Immunogen Pneumovax®23.

Authors:  Alena Roth; Stephanie Glaesener; Katharina Schütz; Almut Meyer-Bahlburg
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

Review 7.  Serum IgA Fc effector functions in infectious disease and cancer.

Authors:  Samantha K Davis; Kevin J Selva; Stephen J Kent; Amy W Chung
Journal:  Immunol Cell Biol       Date:  2020-01-19       Impact factor: 5.126

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.